scopolamine IV
Selected indexed studies
- Pharmacokinetics and pharmacodynamics in clinical use of scopolamine. (Ther Drug Monit, 2005) [PMID:16175141]
- Intrahippocampal Norleucine¹-Angiotensin IV mitigates scopolamine-induced spatial working memory deficits. (Peptides, 2010) [PMID:20816712]
- Neuropharmacological Study on Capsaicin in Scopolamine-injected Mice. (Curr Alzheimer Res, 2023) [PMID:38213170]
_Worker-drafted node — pending editorial review._
Connections
scopolamine IV is a side effect of
Sources
- Pharmacokinetics and pharmacodynamics in clinical use of scopolamine. (2005) pubmed
- Intrahippocampal Norleucine¹-Angiotensin IV mitigates scopolamine-induced spatial working memory deficits. (2010) pubmed
- Neuropharmacological Study on Capsaicin in Scopolamine-injected Mice. (2023) pubmed
- [Interest of scopolamine as a treatment of major depressive disorder]. (2016) pubmed
- Attenuation of scopolamine-induced spatial learning impairments by an angiotensin IV analog. (1998) pubmed
- Cannabinoid agonist WIN55,212-2 prevents scopolamine-induced impairment of spatial memory in rats. (2025) pubmed
- Ranuncoside's attenuation of scopolamine-induced memory impairment in mice via Nrf2 and NF-ĸB signaling. (2023) pubmed
- Therapeutic Role of l-Theanine in Mitigating Cognitive Dysfunction and Neuropathology in Scopolamine-Treated Mice. (2025) pubmed
- Multitarget Effect of 2-(4-(Methylthio)phenyl)-3-(3-(piperidin-1-yl)propyl)thiazolidin-4-one in a Scopolamine-Induced Amnesic Rat Model. (2021) pubmed
- Current Evidence for the Role of Rapid-Acting Antidepressants in Bipolar Depression: A Perspective and Plan for Action. (2025) pubmed